HRMY Stock Analysis: Buy, Sell, or Hold?
HRMY - Harmony Biosciences Holdings, Inc. Common Stock
$33.28
-0.49 (-1.45%)
▼
5d:
-5.45%
30d:
+9.33%
90d:
+19.67%
HOLD
LOW Confidence
Analysis Updated: Jun 18, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When HRMY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: HRMY shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: HRMY shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$63.04
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$39.14
15.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 5.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HRMY is currently trading at $33.28, which is considered slightly high relative to its 30-day fair value range of $30.27 to $33.65. The stock's valuation (Forward PE: 6.0) is in line with its historical norms (5.8). At these levels, the market is pricing in 0.7% annual earnings growth.
Technical Outlook: Technically, HRMY is showing sideways momentum. Immediate support is located at $32.00, while resistance sits at $35.95.
Market Sentiment: HRMY has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $44.36 (+33.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HRMY is showing sideways momentum. Immediate support is located at $32.00, while resistance sits at $35.95.
Market Sentiment: HRMY has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $44.36 (+33.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$30.27 -
$33.65
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.5%
Protect Your Profits
Holding HRMY? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 33.3% below Wall St target ($44.36)
- BULLISH: Expecting earnings turnaround to 0.7% growth with 16.6% revenue growth
- CAUTION: Recommendation downgraded due to -5.5% 5-day decline
Trading Range Analysis
30-Day Trading Range
$30.27 -
$33.65
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$3.15
(9.5%)
Support & Resistance Levels
Support Level
$32.00
Resistance Level
$35.95
Current Trend
Sideways
Technical data as of
Jun 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.96
Wall Street Target
$44.36
(+33.3%)
Revenue Growth (YoY)
16.6%
Earnings Growth (YoY)
-29.5%
Profit Margin
16.2%
Valuation Premium vs History
+0.7% premium
PE vs Historical
6.0 vs 5.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.7%
(market-implied from PE analysis)
1-Year Target
$33.51
(+1%)
2-Year Target
$33.75
(+1%)
3-Year Target
$33.98
(+2%)
3-Yr Target (if PE normalizes)
(PE: 6→6)
PE COMPRESSION
$33.06
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 27.1%)
$249.31
(+649%)
Base:
(SPY PE: 6.0, Growth: 27.1%)
$68.25
(+105%)
Bear:
(PE: 5.1, Growth: 27.1%)
$58.02
(+74%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (6x PE) as earnings recover.
Trailing PE: 13.62 | Current EPS (TTM): $2.48
Bull Case
$74.29
(+123%)
Analyst growth 100.0%, PE expands to 15.0
Base Case
$67.54
(+103%)
Market implied 100.0%, PE stable at 13.6
Bear Case
$22.96
(-31%)
Severe decline -20.0%, PE contracts to 11.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 18, 2026 8:29 PM ET
Data refreshes hourly during market hours. Next update: 9:29 PM
Data refreshes hourly during market hours. Next update: 9:29 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HRMY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Sandip Kapadia
SELL
3746 shares
2026-01-26
Sandip Kapadia
SELL
20961 shares
2026-01-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 57 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$439 | 52 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 65 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 57 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 45 HOLD |
Advanced HRMY Option Strategies
Professional options setups generated by AI based on today's HRMY price and gamma walls.
